ABBV catalysts
Catalysts and events linked to ABBV, newest first.
DateCardAvg 5d
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-09-21Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surgeABBV BMY
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2ABBV BMY
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surgeABBV BMY
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS SurgeABBV BMY
- 2026-09-15Citadel expands AbbVie stake over 500% in Q2 defensive positioning moveABBV
- 2026-09-15AbbVie Advances 1.8% to $261.70 Following 500% Citadel Stake ExpansionABBV
- 2026-09-15AbbVie Gains 1.8% Following Citadel 500% Stake Increase in Defensive RotationABBV
- 2026-09-15Citadel Expands AbbVie Holding by Over 500% as Defensive Dividend Yield Draws CapitalABBV
- 2026-09-15Citadel Expands AbbVie Stake by Over 500% in Defensive RotationABBV
- 2026-09-15Citadel increases AbbVie position by over 500% amid defensive yield rotationABBV
- 2026-09-15Citadel Expands AbbVie Stake by Over 500% in Defensive RotationABBV
- 2026-09-15AbbVie Gains 1.8% Following Citadel 500% Stake Increase in Defensive RotationABBV
- 2026-09-15Citadel Expands AbbVie Holding by Over 500% as Defensive Dividend Yield Draws CapitalABBV
- 2026-09-15AbbVie Advances 1.8% to $261.70 Following 500% Citadel Stake ExpansionABBV
- 2026-09-15Citadel increases AbbVie position by over 500% amid defensive yield rotationABBV SPY+2.11%
- 2026-09-15Citadel Expands AbbVie Position Over 500% as Defensive Dividend Demand RisesABBV
- 2026-09-15AbbVie Advances 1.8% to $261.70 Following 500% Citadel Stake ExpansionABBV
- 2026-09-15Citadel Expands AbbVie Position Over 500% in Q2 Amid Defensive RotationABBV
- 2026-09-15Citadel increases AbbVie stake over 500% amid institutional yield rotationABBV
- 2026-09-15Citadel Expands AbbVie Position Over 500% as Defensive Dividend Demand RisesABBV ABT
- 2026-09-15Citadel Expands AbbVie Position Over 500% Amid Defensive Rotation and Dividend DemandABBV ABT
- 2026-09-15Citadel Expands AbbVie Holding by Over 500% as Defensive Dividend Yield Draws CapitalABBV ABT
- 2026-09-15Citadel Expands AbbVie Stake by Over 500% in Defensive RotationABBV
- 2026-09-15AbbVie Gains 1.8% Following Citadel 500% Stake Increase in Defensive RotationABBV JPM
- 2026-09-15Citadel expands AbbVie stake over 500% in Q2 defensive positioning moveABBV
- 2026-09-15Citadel Expands AbbVie Stake by Over 500% in Q2 2026ABBV SPY+2.11%
- 2026-09-15Citadel increases AbbVie position by over 500% amid defensive yield rotationABBV SPY+2.11%
- 2026-09-15Citadel Expands AbbVie Stake Over 500% as High Yields Drive Defensive RotationABBV
- 2026-09-13Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoYABBV LLY
- 2026-09-13Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1ABBV LLY
- 2026-09-13Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New LaunchesABBV LLY
- 2026-09-12Eli Lilly immunology sales reach $2.6B in H1 2026 led by Taltz, Ebglyss, and OmvohABBV LLY
- 2026-09-12Eli Lilly Immunology Division Reaches $2.6B in H1 2026 on Taltz and New LabelsABBV LLY
- 2026-09-12Eli Lilly Immunology Division Generates $2.6B in H1 2026 RevenueABBV LLY
- 2026-09-12Eli Lilly immunology division generates $2.6B in H1 revenue (+9% YoY) via M&A pushABBV LLY
- 2026-09-12Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assetsABBV LLY
- 2026-09-12Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A PipelineABBV LLY
- 2026-09-12Eli Lilly Immunology Division Reaches $2.6B H1 Sales on 9 Percent GrowthABBV LLY
- 2026-09-12Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoYABBV LLY
- 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologicsABBV
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 on Biologics ExpansionABBV REGN
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGRABBV LLY
- 2026-09-06Atopic Dermatitis Biopharma Market Projected to Reach $33.4B by 2035 at 7.7% CAGRABBV LLY REGN
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics DemandABBV LLY REGN
- 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologicsABBV REGN
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.